Stockreport

Johnson & Johnson Reports Sustained Efficacy of IMAAVY for Generalized Myasthenia Gravis [TheStreet.com]

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF that IMAAVY (nipocalimab-aahu) maintains disease control in adults with generalized myasthenia gravis through 120 weeks of follow-up. The comprehensive study tracked 153 [Read more]